Pharmacokinetic (PK) guided optimization of 5-fluorouracil (5-FU) dosing in the treatment of patients with colorectal cancer (CRC)

被引：0
|
作者：
Goal, Gaurav
Chu, Edward
Sun, Min
Meisner, Dennis James
Lee, James J.
机构：
[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[2] UPMC Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14561
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Photosensitivity due to 5-fluorouracil (5-FU)
    von Moos, R
    Sauter, C
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1999, 129 (1-2) : 52 - 52
  • [32] Long-term weekly treatment of advanced colorectal cancer (CRC) with fluorouracil (5-FU) and leucovorin (LV): 5 year-results of a multicentric phase II trial of 5-FU pharmacokinetic monitoring in 152 patients
    Lamezec, B
    Alleaume, C
    Gamelin, E
    Goudier, MJ
    Cailleux, PE
    DanquechinDorval, E
    Sire, M
    Maillet, ML
    Maigre, M
    Gesta, P
    Maillart, P
    Larra, F
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 726 - 726
  • [33] THE RELATIONSHIP BETWEEN PLASMA PHARMACOKINETICS AND TISSUE METABOLITES OF 5-FLUOROURACIL (5-FU) IN PATIENTS WITH COLORECTAL-CANCER
    FINAN, PJ
    CHISHOLM, EM
    WOODHOUSE, L
    GILES, GR
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1987, 13 (04): : 349 - 353
  • [34] Trimetrexate (TMTX) modulation of 5-fluorouracil leucovorin (5-FU/LV) for advanced colorectal cancer
    Blanke, C
    Kasimis, B
    Schein, P
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 748 - 748
  • [35] 5-FLUOROURACIL (5-FU), METHYL-CCNU, AND VINCRISTINE IN TREATMENT OF ADVANCED COLORECTAL CANCER - PHASE-2 STUDY UTILIZING WEEKLY 5-FU
    MACDONALD, JS
    KISNER, DF
    SMYTHE, T
    WOOLLEY, PV
    SMITH, L
    SCHEIN, PS
    CANCER TREATMENT REPORTS, 1976, 60 (11): : 1597 - 1600
  • [36] Preoperative chemoradiotherapy with 5-fluorouracil (5-FU) or 5-FU/oxaliplatin (5FU/OX) for rectal cancer is a feasible treatment strategy in the elderly
    Dolinsky, C. M.
    Mahmoud, N. N.
    Mick, R.
    Sun, W.
    Whittington, R.
    Solin, L. J.
    Haller, D. G.
    O'Dwyer, P.
    Fry, R. D.
    Metz, J. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S308 - S308
  • [37] Adjuvant therapy (AT) with raltitrexed (RAL) in colorectal cancer (CRC) patients (pts) intolerant of 5-fluorouracil (5FU).
    Wilson, K. S.
    Barnett, J. B.
    Gill, S.
    Khoo, K. E.
    Fitzgerald, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 163S - 163S
  • [38] Does the dose of leucovorin (LV) matter with 5-fluorouracil (5FU) in colorectal cancer (CRC)?
    Biagi, James Joseph
    Coakley, Nadia
    Earle, Craig
    Erlichman, Charles
    Fields, Anthony L. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [39] SALVAGE TREATMENT WITH CISPLATIN (CDDP) AND 5-FLUOROURACIL (5-FU) IN ADVANCED BREAST-CANCER PATIENTS
    PRONZATO, P
    AMOROSO, D
    BERTELLI, G
    LIONETTO, R
    ARDIZZONI, A
    CONTE, PF
    ROSSO, R
    GALLOTTI, P
    BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (01) : 108 - 108
  • [40] Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer
    Tsavaris, N
    Kosmas, C
    Gennatas, K
    Vadiaka, M
    Skopelitis, E
    Xila, V
    Rokana, S
    Margaris, E
    Zografos, G
    Papastratis, G
    Kouraklis, G
    JOURNAL OF CHEMOTHERAPY, 2002, 14 (04) : 406 - 411
12345